MiRNA as markers for the diagnostic screening of colon cancer

Expert Review of Anticancer Therapy

Volumn 14, Issue 4, 2014, Pages 463-485

  Ahmed, Farid E ^a  

^a GEM Tox Labs   (United States)

Author keywords

bioinformatics; diagnosis; histopathology; microarrays; quality control; RNA; RT qPCR; statistics

Indexed keywords

MICRORNA;

ABDOMINAL PAIN; BIOINFORMATICS; CANCER MORTALITY; CANCER SCREENING; COLON CANCER; COLONOSCOPY; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTRAST ENHANCEMENT; DNA REPAIR; EARLY DIAGNOSIS; GENE MUTATION; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MORBIDITY; OCCULT BLOOD; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW;

COLONIC NEOPLASMS; EARLY DETECTION OF CANCER; FECES; GENOMICS; HUMANS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; STATISTICS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84896910121     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.869479     Document Type: Review

References (177)

1. Peterson NB, Murff HJ, Ness RM, Dittus RS. Colorectal cancer screening among men and women in the United States. J. Womens Health 16, 57-65 (2007).
2. Mandel JS. Screening for colorectal cancer. Gastrointestinal. Clin. North Am. 37, 97-115 (2008).
3. Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nature Rev. Cancer 5, 199-209 (2005).
4. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009. A review of current American Cancer Society Guidelines and issues in cancer screening. CA Cancer J. Clin. 59, 27-41 (2002).
5. Ahmed FE. Colon cancer: prevalence, screening, gene expression and mutation, and risk factors and assessment. J. Env. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 21(2), 65-131 (2003).
6. Davidson LA, Lupton JR, Miskovsky E et al. Quantification of human intestinal gene expression profiling using exfoliated colonocytes: a pilot study. Biomarkers 8, 51-61 (2003).
7. Ahmed FE, Jeffries CD, Vos PW et al. Diagnostic microRNA markers for screening sporadic human colon cancer and ulcerative colitis in stool and tissue. Cancer Genomics Proteomics 6, 281-296 (2009).
8. Ahmed FE, Vos P, iJames S et al. Transcriptomic molecular markers for screening human colon cancer in stool & tissue. Cancer Genomics Proteomics 4, 1-20 (2007).
9. Ahmed FE, Ahmed NC, Vos PW et al. Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle. Cancer Genomics Proteomics 10(3), 93-113 (2013).
10. Ahmed FE, Ahmed NC, Vos PW et al. Diagnostic microRNA markers to screen for sporadic human colon cancer in blood. Cancer Genomics Proteomics 9, 179-192 (2012).
11. Ahlquist DA. Fecal occult blood testing for colorectal cancer. Can we afford to do this? Gastroenterol. Clin. North Am. 26, 41-55 (1997).
12. Centers for Disease Control and Prevention. Increased use of colorectal cancer test: United States, 2002 and 2004. MMWR Mortal. Wkly 55, 208-311 (2006).
13. Nair P, Lagerhola S, Dutta S et al. Comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 125, 422-428 (2006).
14. Kohler BA, Ward E, McCarthy BJ et al. Annual report to the nation on the status of cancer, 1975-2007, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116, 544-573 (2010).
15. DeRoux SJ, Sgarlato A., Upper and lower gastrointestinal endoscopy mortality: the medical examiners perspective. Forensic, Sci. Med. Pathol, 8, (1) 4-12, 2012
16. Cheng L, Eng G, Nieman L et al. Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. Am. J. Clin. Oncol. 34, 573-580 (2011).
17. Huxley RR, Ansary-Moghaddam A, Clifton P et al. The impact of dietary and lifestyle risk factors on risk of colorectal cancer: a quantitative overview of the epidemiological evidence. J. Natl Cancer Inst. 125, 171-180 (2009).
18. Morikawa T, Kato J, Yamaji et al. Comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 125, 422-428 (2006).
19. Senore C, Ederle A, Fantin A et al. Acceptability and side-effects of colonoscopy and sigmoidoscopy in a screening setting. J. Med. Screen. 18(3), 128-134 (2011).
20. Newcomb PA, Storer BE, Morimoto LA et al. Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J. Natl Cancer Inst. 99, 622-625 (2003).
21. Yamai Y, Mitsushima T, Ikuma H et al. Right-sided shift of colorectal adenomas with aging. Gastrointest. Endoscopy 63, 453-458 (2006).
22. Gatto NM, Frucht H, Sundarararjan V et al. Risk of perforation after colonoscopy or sigmoidoscopy: a population based study. J. Natl Cancer Inst. 95, 230-236 (2002).
23. Birkenkamp-Demtroder K, Olesen SH. Differential gene expression in colon cancer of the ceacum versus the sigmoid and rectosigmoid. Gut 54, 374-384 (2003).
24. Gervaz P, Bouzourene H, Gerottini JP. Dukes B colorectal cancer: distinct genetic categories and clinical outcome based on proximal or distal tumor locations. Dis. Colon Rectum 44, 364-372 (2001).
25. Ahlquist DA, Shuber AP. Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin. Chim. Acta 315, 151-157 (2002).
26. Bressler B, Paszat LF, Vinden C et al. Colonoscopic miss rates for right-sided colon cancer: population-based study. Gastroenterology 123, 452-456 (2004).
27. Mulhall BP, Veerappan GR, Jackson J. Meta-analysis: computed tomographic colonography. Ann. Intern. Med. 142, 635-650 (2005).
28. Kealey SM, Dodd JD, MacEneaney PM et al. Minimal preparation computed tomography instead of barium enema/ colonoscopy for suspected colon cancer in frail elderly patients: an outcome analysis study. Clin. Radiol. 59, 44-52 (2004).
29. Muller HM, Oberwalder M, Fiegl H et al. Methylation changes in fecal DNA: a marker for colorectal cancer screening. Lancet 363, 1283-1285 (2004).
30. Lenhard K, Bommer GT, Asutay S et al. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin. Gastroenterol. Hepatol. 3, 142-149 (2005).
31. Itzkowitz SH, Jandorf L, Brand R et al. Improved fecal DNA test for colorectal cancer screening. Clin. Gastroenterol. Hepatol. 5, 111-117 (2007).
32. Imperiale TF, Ransohoff DF, Itzkowitz SH et al. Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. N. Engl. J. Med. 351, 2704-2714 (2004).
33. Ahmed FE. Liquid chromatography-mass spectrometry: a tool for proteome analysis & biomarker discovery and validation. Exp. Opin. Mol. Diagn. 3, 429-444 (2009).
34. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 128, 192-206 (2005).
35. Traverso G, Shuber A, Levin B et al. Detection of APC mutations in fecal and DNA from patients with colorectal tumors. N. Engl. J. Med. 346, 311-320 (2002).
36. Ahlquist DA, Skoletsky JE, Boynton KA et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119, 1219-1227 (2000).
37. Ladabaum U, Song K. Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology 129, 1151-1126 (2005).
38. Polley AC, Mulholland F, Pin C et al. Proteomic analysis reveals field-wide changes in protein expression in the morphologically normal mucosa of patients with colorectal neoplasia. Cancer Res. 66, 6553-6562 (2006).
39. Xin B, Platzer P, Fink SP et al. Colon cancer secreted protein-2 (CCSP-2) a novel candidate serological marker of colon neoplasia. Oncogene 24, 724-731 (2005).
40. Thomas SN, Zhu F, Schnaar RL et al. Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow. Biorheology 46, 207-225 (2008).
41. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science 212, 43-55 (1981).
42. Smith RA, von Eschenbach AC, Wender R et al. American Cancer Society guidelines for the early detection of cancer: update of the early detection guidelines for prostate, colorectal and endometrial cancers. CA Cancer J. Clin. 51, 38-75 (2001).
43. Ng EKO, Chong WWS, Jin H et al. Differential expression of microRNA in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58, 1375-1381 (2009).
44. Link A, Balaguer F, Shen Y et al. Fecal miRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol. Biomarkers Prev. 19, 1766-1774 (2010).
45. Koga Y, Yasunaga M, Takahashi A et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev. Res. 3, 1435-1442 (2010).
46. Kalimutho M, Del Vecchio BG, Di Cecilia S et al. Differential expression of miR-144 as a novel fecal-based diagnostic marker for colorectal cancer. J. Gastroenterol. 46, 1391-1402 (2011).
47. Kalimutho M, Di Cecilia S, Del Vecchio BG et al. Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br. J. Cancer 24, 1770-17780 (2011).
48. Kunte D P, Delacruz M, Wali R K et al. Dysregulation of microRNAs in colonic field carcinogenesis: implications for screening. PLoS ONE 7, e45591 (2012).
49. Wu CW, Ng SS, Dong YJ et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 61, 739-745 (2012).
50. Cummins JM, He Y, Leary RJ et al. The colorectal microRNome. Proc. Natl Acad. Sci. USA 103, 3687-3692 (2006).
51. Schepler T, Reinert JT, Oslenfeld MS et al. Diagnostic and prognostic microRNAs in Stage II colon cancer. Cancer Res. 68, 6416-6424 (2008).
52. Barbarotto E, Schmittgen TD, Calin GA. MicroRNAs and cancer: profile, profile, profile. Int. J. Cancer 122, 969-977 (2008).
53. Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profile associated with progression and therapeutic outcome in colon adenocarcinoma. J. Am. Med. Assoc. 299, 425-436 (2008).
54. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866 (2006).
55. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005).
56. Yantis RK, Goodarzi M, Zhou XK et al. Clinical, pathological, and molecular features of early-onset colorectal carcinoma. Am. J. Surg. Pathol. 33, 572-582 (2009).
57. Luo X, Burwinke B, Tao S, Brenner J. MicroRNA signatures: Novel biomarkers for colorectal cancers. Cancer Epidemiol. Biomarkers Prev. 20, 1272-1286 (2011).
58. Ahmed FE. Testing for genetically modified organisms (GMOs) in food products. Lab. Plus Intern. 16, 8-16 (2002).
59. Ahmed FE, Vos P. Molecular markers for human colon cancer in stool and blood identified by RT-PCR. Anticancer Res. 24, 4127-4134 (2004).
60. Wang K, Zhang S. Weber J. Baxter D, Galas DJ. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res. 38, 7248-7259 (2010).
61. Arroyo JD, Chevillet JR. Kroh EM et al. Argonaute 2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl Acad. Sci. USA 108, 5003-5008 (2011).
62. Vickers KC, Palmisano BT, Shoucri BM et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 13, 423 (2011).
63. Hunter MP. Detection of microRNA expression in human peripheral microvesicles. PLoS ONE 3, e3694 (2008).
64. Ahmed FE, iJames S, Lysle DL et al. Improved methods for extracting RNA from exfoliated human colonocytes in stool and RT-PCR analysis. Dig. Dis. Sci. 49, 1889-1898 (2004).
65. Mestdagh P, Van Vlierberghe P, De Weer A et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 10, R64 (2009).
66. Bentwich I, Avniel A, Karov Y et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat. Genet. 37, 766-770 (2005).
67. Balcells I, Cirera S, Busk PK. Specific and sensitive quantitative RT-PCR of miRNAs with DNA primers. BMC Biotechnol. 11, 70 (2011).
68. Resnick KE, Alder H, Hagan JP et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 112, 55-59 (2009).
69. Redshaw N, Wilkes T, Whale A et al. A comparison of miRA isolation and RT-qPCR technologies and their effects on quantification accuracy and repeatability. Biotechniques 54, 155-164 (2013).
70. Lee EJ, Gusev Y, Jiang J et al. Expression profiling identifies distinct microRNA signature in pancreatic cancer. Int. J. Cancer 120, 1046-1054 (2007).
71. Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9, 189-198 (2006).
72. Iorio MV, Ferracin M, Liu CG et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65, 7065-7070 (2005).
73. Miska EA, Alvarez-Saavedra E, Townsend M et al. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol. 5, R68 (2004).
74. Kim J, Krichevsky A, Grad Y et al. Identification of many microRNAs that copurify with polyribosomes in mammalian neurons. Proc. Natl Acad. Sci. USA 101, 360-365 (2004).
75. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103, 2257-2261 (2006).
76. Aandres E, Cubedo E, Agirre X et al. Identification by real-time PCR of mature microRNAs differentially expressed in colorectal cancer and non-tumor tissues. Mol. Cancer 5, 29 (2006).
77. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 33, 5394-5403 (2005).
78. Shi B, Stepp-Lorenzino L, Prisco M et al. MicroRNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J. Biol. Chem. 282, 32582-32590 (2007).
79. Calin GA, Ferracin M, Cimmino A et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353, 1793-1801 (2005).
80. Eis PS, Tam W, Sun L et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl Acad. Sci. USA 102, 3627-3632 (2003).
81. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and downregulation of microRNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99, 15524-15529 (2002).
82. Nybo K, Lo PCH. Optimal miRNA RT-qPCR. Biotechniques 54. 113 (2013).
83. Ahmed FE, Vos PW, Clark J et al. Differences in mRNA and microRNA expression profiles in human colon adenocarcinoma HT-29 cells treated with either intensity-modulated radiation therapy (IMRT), or conventional radiation therapy (RT). Cancer Genomics Proteomics 6, 109-128 (2009).
84. Wu F, Zikusoka M, Trindade A et al. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory particle 2-a. Gastroenterology 135, 1626-1635 (2008).
85. Lu M, Zhang Q, Deng M et al. An analysis of human microRNA and disease associations. PLoS ONE 3, e3420 (2008).
86. Ahmed FE. Expression microarray proteomics and the search for cancer biomarkers. Curr. Genomics 7, 399-426 (2006).
87. Ahmed FE. Quantitative real-time RT-PCR: application to carcinogenesis. Cancer Genomics. Proteomics. 2, 317-332 (2005).
88. Lewis BP, Shih IH, Jones-Rhodes MW et al. Prediction of mammalian microRNA targets. Cell 115, 787-789 (2003).
89. Gusev Y. Computational methods for analysis of cellular functions and pathways collectively targeted by differentially expressed microRNA. Methods 44, 61-72 (2008).
90. Gusev Y, Schmittgen TD, Lerner M et al. Computational analysis of biological functions and pathways collectively targeted by coexpressed microRNAs in cancer. BMC Bioinformatics 8(Suppl. 7), S16 (2007).
91. Ahmed FE. The role of microRNA in carcinogenesis and biomarker selection: a methodological perspective. Exp. Rev. Mol. Diagn. 7, 569-603 (2007).
92. UICC TNM Classification of Malignant Tumors (6th Edition). Sobin LH, Wittekind CH (Eds). John Wiley, NY, USA, 170-173 (2002).
93. AJCC Cancer Staging Manual (6th Edition). Greene FL, Page DL, Fleming ID (Eds). Springer-Verlag, NY, USA (2002).
94. DeBakey ME. MicroRNA and colorectal cancer. World J. Surg. 33, 638-646 (2009).
95. Zhou X, Ruan J, Wang G, Zhang W. Characterization and identification of microRNA core promoters in trout model species. PLoS Comput. Biol. 337 (2005).
96. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 39(Suppl. 1), D152-D157 (2011).
97. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism and function. Cell 116, 281-297 (2004).
98. Reinhart BJ, Slack FJ, Basson M et al. RNA regulates developmental timing in Caenorhabditis elegans. Nature 403, 901-906 (2000).
99. Xu P, Guo M, Hay BA. MicroRNAs and the regulation of cell death. Trends Genet. 20, 617-624 (2004).
100. Chang-Zheng C. MicroRNAs as oncogenes and tumor supressors. N. Engl. J. Med. 353, 1768-1771 (2005).
101. Ahmed FE. Molecular markers that predict response to colon cancer therapy. Exp. Rev. Mol. Diagn. 5, 353-375 (2005).
102. Lanza G, Ferracin M, Gafa R et al. mRNA/ microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol. Cancer 6, 54 (2007).
103. Kiriakidou M, Nelson PT, Kouranov A et al. A combined computationalexperimental approach predicts human microRNA targets. Genes Dev. 18, 1165-1178 (2004).
104. John BB, Enright AJ, Aravin A et al. Human microRNA target. PLoS Biol. 2, e363 (2004).
105. Krek A, Grun D, Poy MN et al. Combinational microRNA target predictions. Nat. Genet. 37, 495-500 (2005).
106. Stark A, Brennecke J, Bushati N et al. Animal microRNAs confers robustness to gene expression and have a significant impact on 3UTR evaluation. Cell 123, 1133-1146 (2005).
107. Oberg AL, French AJ, French AJ et al. miRNA expression in colon polyps provide evidence for a multihit model of colon cancer. PLoS ONE 6, e20465 (2011).
108. Valadi H, Elkstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654-659 (2007).
109. Ahmed FE. Laser microdissection: application to carcinogenesis. Cancer Genomics Proteomics 3, 217-226 (2006).
110. Jensen SG, Lamy P, Rasmussen MH et al. Evaluation of two commercial global miRNA expression profiling platforms for detection of less abundant miRNAs. BMC Genomics 12, 435 (2011).
111. Chen C, Ridzon DA, Broomer AJ et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33, e179 (2005).
112. Tellman G. The E-method: a highly accurate technique for gene-expression analysis. Nat. Methods 3, 1-2 (2006).
113. LightCycler Software-, Version 3.5. Roche Molecular Biochemicals, Mannheim, Germany, 64-79 (2001).
114. Luu-The V, Paquet N, Calvo E, Cumps J. Improved real-time RT-PCR method for high-throughput measurements using second derivative calculation and double correction. Biotechniques 38, 287-293 (2005).
115. Thellin O, Zorzi W, Lakaye B et al. Housekeeping genes as internal standards: use and limits. J. Bitechnol. 76, 291-296 (1999).
116. Vandesompele J, De Preter K, Pattyn F et al. Accurate normalization of real-time quantitative RT-PCR by geometric average of multiple internal control genes. Genome Biol. 3, 7 (2010).
117. DeMuth J P, Jackson C M, Weaver D A et al. The gene expression index cmyc x E2F-1/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 19, 18-29 (1998).
118. Nagan CY, Yamamoto H, Seshimo I et al. A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. J. Surg. Oncol. 95, 652-662 (2007).
119. Pepe MS, Feng Z, Janes H et al. Pivotal evaluation of the occurrence of a biomarker used for classification or prediction: standards for study design. of Cancer. J. Natl Cancer Inst. 100, 1432-1438 (2008).
120. Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc. Natl Acad. Sci. USA 103, 5923-5928 (2006).
121. A-Z of Quantitative PCR. Bustin SA (Ed.). International University Line, La Jolla, CA, USA (2004).
122. Tichopad A, Dilger M, Schwarz G, Pfaffl MW. Standardised determination of real-time PCR efficiency from a single reaction setup. Nucleic Acids Res. 31, 21-33 (2003).
123. Bustin SA, Benes V, Garson JA et al. The MIQUE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55, 611-622 (2009).
124. Kraemer HC. Evaluating Medical Tests: Objective and Quantitative Guidelines. Sage Publications, Newsburry Park, CA, USA (1992).
125. Sureh KP, Chandrashekare S. Sample size estimation and power analysis for clinical research studies. J. Hum. Reprod. Sci. 5, 7-13 (2013).
126. Statistical models for cancer studies. In: Models to Analyze Strategies in the General Population. Cornell RG (Ed.). Marcel Dekker, NY, USA, 346-347, 1984.
127. Ripley BD. Classification. In: Encyclopedia of Statistical Sciences, Volume 1. Wiley- Interscience Publication, NY, USA (1997).
128. Moore DS, McCabe GP, Craig B. Introduction to the Practice of Statistics (6th Edition). W.H. Freeman & Company, St. Louis, MO, USA (2009).
129. Nagan CY, Yamamoto H, Seshimo I et al. A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. J. Surg. Oncol. 95, 652-662 (2007).
130. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19, 368-375 (2003).
131. Pawitan Y, Michiels S, Kosciely S, Gusnato A, Polner A. False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 21, 3017-3024 (2005).
132. Tang Y, Ghosal S, Roy A. Nonparametric Bayesian estimation of positive false discovery rates. Biometrics 63, 1126-1134 (2007).
133. Choi H, Nesvizhskii AI. False discovery rates and related statistical concepts in mass spectrometry-based proteomics. J. Proteom. Res. 7, 47-50 (2008).
134. Earl-Slatter A. Cross validation. In: The Handbook of Clinical Trials and Other Research. Radcliff Medical Press Ltd, Oxford, UK (2002).
135. Efron B, Tibshirani RJ. An introduction to the Bootstrap. Chapman and Hall, NY, USA (1993).
136. Yildiz OY, Aslan A, Alpagdin E. Multivariate statistical tests for comparing classification algorithms. In: Learning and Intelligence Optimization. Coello CA (Ed.). Springer-Verlag, Berlin, Germany, 1-5 (2011).
137. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29-36 (1982).
138. Ringner M. What is principal component analysis? Nat. Biotechnol. 26(3), 303-304 (2008).
139. Wegman E. Hyperdimensional data analysis using parallel coordinates. J. Am. Stat. Assoc. 85(411), 664-675 (1990).
140. Gabriel KR. Odoroff CL. Biplots in biomedical research. Stat. Med. 9(5), 469-485 (1990).
141. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
142. Esteller M. Epigenetic changes in cancer. The Scientist. 25, 34-39 (2011).
143. Irizarry RA, Ladd-Acosta C, Wen B et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41, 178-186 (2009).
144. Herman JG, Baylin SB. Gene silencing in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042-2054 (2003).
145. Hansen KD, Timp W, Corrada H et al. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 43, 768-775 (2011).
146. Sarver AL, French AJ, Borralho PM et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer 9, 401 (2009).
147. Earle JSL, Luthra R, Romans A et al. Association of microRNA expression with microsatellite instability status in colorectal adenocarcinoma. J. Mol. Diagn. 12, 433-440 (2010).
148. Balaguer F, Moreira L, Lozano JJ et al. Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin. Cancer Res. 17, 6239-6249 (2011).
149. Tuddenham L, Wheeler G, Ntounia-Fousara S et al. The cartilage-specific microRNA- targets histone deacetylase 4 in mouse cells. FEBS Lett. 580, 4214-4217 (2006).
150. Costa Y, Speed RM, Gautier P et al. Mouse MAELSTROM: the link between miotic silencing of unsynapsed chromatin and microRNA pathways? Hum. Mol. Genet. 15, 2324-2334 (2006).
151. Rajewsky N. microRNA target predictions in animals. Nat. Genet. 38. S8-S13 (2006).
152. Saito Y, Liang G, Egger G et al. Specific activation of microRNA-127 with downregulation of the protooncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9, 435-443 (2006).
153. Lujambio A, Calin GA, Villanueva A et al. A microRNA DNA methylation signature for human cancer metastasis. Proc. Natl Acad. Sci. USA 105, 13556-13561 (2008).
154. Dews M, Homayouni A, Yu D et al. Augmentation of tumor angiogenesis by a myc-activated microRNA cluster. Nat. Genet. 38, 1060-1065 (2006).
155. Fazi F, Rosa A, Fatica A et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/ EBPalpha regulates human granulopoiesis. Cell 123, 819-831 (2005).
156. Koss Diagnostic Cytology and Histopathologic Bases (5th Edition). Lippincott, Williams & Wilkins, PA, USA (2005).
157. Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am. J. Pathol. 163, 2139-2148 (2003).
158. Petrelli NJ, Letourneau R, Weber T et al. Accuracy of biopsy and cytology for the preoperative diagnosis of colorectal adenocarcinoma. J. Surg. Oncol. 71, 46-49 (1999).
159. Matsushita HM, Matsumura Y, Moriya Y et al. A new method for isolating colonocytes from naturally evacuated feces and its clinical application to colorectal cancer diagnosis. Gastroenterology 129, 1918-1927 (2005).
160. Simpson RJ, Lim JE, Moritz RL, Mathivanan S. Exosomes: proteomic insights and diagnostic potential. Exp. Rev. Proteomics 6, 267-283 (2009).
161. Baker M. Digital PCR hits its stride. Nat. Methods 9, 541-544 (2007)
162. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 97, 1180-1184 (2005).
163. American Cancer Society., www.cancer.org.
164. Shaffer J, Schlumpberger M, Lader E. miRNA Profiling from Blood - Challenges and Recommendations. Qiagen Notes, Frederic, MD, USA, 1-10 (2012). www.qiagen.com
165. miRBase: the microRNA database. http://mirbase.org
166. TargetScan Release 6.2 (2012). www.targetscan.org
167. Diana lab tools. www.diana.pcbi.upenn.edu
168. miRNA. www.microrna.org
169. PicTar. http://pictar.bio.nyu.edu
170. Protein Evolution (Prof. Rob Russell). http://russell.embl-heidelberg.dr
171. Swiss Institute of Bioinformatics. RNA regulatory networks. www.mirz.unibas.ch
172. miRNA Targets by Weighting RISC-IP Enriched Parameters. http://146.189.76.171/query
173. Segal Lab of computational biology. PITA catalogs of predicted microRNA targets. http://genie.weizmann.ac.il/pubs/mir07/ mir07-data.html
174. Welcome to the Frontpage. www.mld.dk/publicationnormfinder.htm
175. The Comprehensive R Archive Network. http://cran.r-project.org
176. NCSS Statistical Software. www.ncss.com
177. RT2 Profiler PCR Array Data Analysis v3.5. http://pcrdataanalysis. sabiosciences.com, 2013.